Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Atezolizumab in Patients With Non-Metastatic Resectable High-Risk Cutaneous Melanoma

NCT04020809 is registered in ClinicalTrials.gov with The Methodist Hospital Research Institute as lead sponsor.

NCT NCT04020809
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04020809 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Atezolizumab in Patients With Non-Metastatic Resectable High-Risk Cutaneous Melanoma
Lead sponsor
The Methodist Hospital Research Institute
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 25, 2020
Completion date
October 1, 2026
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous melanoma